Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia

Inclusion Criteria: * If female, non-lactating and at no risk or pregnancy (post-menopausal or must use adequate birth control) * Must be a suitable candidate for oral antibiotic therapy and must be able to swallow capsules intact * Must have a clinical diagnosis of CAP based on clinical evidence * Must have a chest radiograph demonstrating new or persistent/progressive infiltrates * Must be able to produce sputum Exclusion Criteria: * Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval * Patients with CAP that, in the investigator's judgment, is severe enough to require hospitalization for intravenous antibiotic therapy and/or supplemental oxygen therapy with ICU support * Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary tuberculosis or infection with other mycobacteria or fungi, known bronchial obstruction, a history of post-obstructive pneumonia, other confounding respiratory diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess, empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory infection (chronic obstructive pulmonary disease \[COPD\] is not exclusionary) * Infection acquired in a hospital, nursing home, or other long-term care facility, or hospitalization for any reason within the previous 14 days * Treatment with any antibiotics within the past 7 days prior to randomization, unless documents to be a treatment failure(72 hours treatment and not responding) * Anticipation of the requirement for additional treatment with non-study antibacterials for any reason during the patient's participation in the study * Treatment with chemotherapeutic agents or oncolytics during the 6 months prior to randomization or anticipated requirement for such agents during the course of the study * Known or suspected CNS disorder that may predispose the patient to seizures or lower the seizure threshold